ความปลอดภัยและประสิทธิผลของยา Deferiprone (GPO-L-ONE®) ชนิดรับประทาน ในผู้ป่วยเด็กโรคโลหิตจางธาลัสซีเมียที่มีภาวะเหล็กเกินของสถาบันสุขภาพเด็กแห่งชาติ มหาราชินี

Sipornswan P, Pongtanakul B, Viprakrasit V.Prospective clinical evaluation for serious adverse events and complications due to deferiprone (L-1) in pediatric patients. Journal of Hematol & Trandfudion Midicine 2008:33.

Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, et al. Rick factors for death in patients with beta-thalassemia major: results of a case-control study.Haematologica 2006; 91:1420-1.

Viprakrasit V. Clinical practice guidline for deferiprone in patients with iron overload: The GovernmentPharmaceutical Organization (GPO) of Thailand. Bangkok; 2009.

DRUGDEX® Evaluations Deferiprone. In: DRUGDEX® System. MICROMEDEX Inc., Greenwood Village, Colorado (Edition expires [unknwn]).

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739-61.

Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Mauugsub W, Sriphen K, et al. Clinical trail of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol2003; 122:305-10.

Viprakrasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, et al. Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematolo 2013; 251-60.